A 6-week Randomized, Double-blind, Placebo-controlled, Comparator Referenced, Multicenter Trial of Vabicaserin in Subjects With Acute Exacerbation of Schizophrenia

Vabicaserin has been developed for the treatment of schizophrenia. It was evaluated in this randomized, double- blind, placebo controlled and olanzapine-referenced phase 2a study. Hospitalized subjects with exacerbation of schizophrenia were selected and randomized into one of four treatment arms: vabicaserin 200 mg/day or 400 mg/day, olanzapine 15 mg/day or placebo for a 6-week treatment. This study showed that vabicaserin was well tolerated and efficacious in the 200 mg/day dose arm, which demonstrated proof of concept in subjects with acute exacerbation of schizophrenia. 10 (13.0) 9 (11.0) 11 (14.3) 10 (13.0) 40 (12.8) Investigations 10 (13.0) 9 (11.0) 10 (13.0) 20 (26.0) 49 (15.7)